NEWS

Press Release NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)

Press Release New evidence of NeoImmuneTech’s NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors

Press Release NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting

Press Release NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting

Press Release NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab

Press Release NeoImmuneTech Welcomes New Members to its Scientific Advisory Board

Press Release FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme

Press Release A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

Press Release NeoImmuneTech to Present at Upcoming BIO International Convention

Press Release NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors